Transaction #8795 · Form 4 · 0001213900-25-111681
Vyome Holdings, Inc · Stock award · Stock Option (right to buy)
Vyome Holdings, Inc · Transacted November 13, 2025 · Filed November 17, 2025
What does this filing report?
An SEC Form 4 filing for Vyome Holdings, Inc records a stock award involving Stock Option (right to buy) on November 13, 2025. The reported quantity was 615,149. The filing date is November 17, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Vyome Holdings, Inc
- Company CIK
- 0001427570
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 615,149
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 615,149
- Ownership description
- Not reported
- SEC acceptance time
- Nov 17, 2025, 7:35 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Nelabhotla Venkateswarlu ↗
President and CEO · Director
CIK 0002083546
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 615,149
- Conversion / exercise price
- 0.66
- Exercise date
- November 13, 2025
- Expiration date
- July 30, 2035
Filing footnotes & remarks
- F1
- Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.
- F2
- Pursuant to the Merger Agreement the reporting person was granted options to purchase 615,149 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.